Sponsor Name:  Radius Health, Inc.  
Protocol Number:  BA058 -05-028 
Protocol Version and Date:  Original, V1.0 dated 09 July 2021  Page 1 of 63 
Confi dential Clinical Study Protocol 
A Retrospective, Observational Cohort Study Evaluating the 
Effectiveness and Cardiovascular Safety of Abaloparatide in 
Postmenopausal Women New to Anabolic Therapies  
This study will be conducted according to the protocol and in compliance with 
International Council for Harmonisation (ICH) Good Clinical Practice (GCP), Health 
Insurance Portability and Accountability Act  (HIPAA) guidelines, the ethical principles 
stated in the Declaration of Helsinki, and other applicable regulatory requirements.  
Protocol N umber:  BA058-05-028 
Version Number:  Original 
Version Date:  V1.0, 09 Ju ly 2021 
IND Number:  N/A  
NCT Number:  Requested  
Active Ingredient:  Abaloparatide , a novel synthetic peptide analogue of 
PTHrP (human parathyroid hormone-related protein)  
Country of Study: United States of America  
Sponsor:  Radius Health, Inc. (Radius)  
22 Boston Wharf Road, 7th Floor 
Boston, Massachusetts 02210 United States of Americ a
 
Telephone: (617) 551-4700  
Fax: (617) 551-4701 
Contact:   
Radius Health, Inc.  
 
Cl
inical Research 
Organization: PRA Health Sciences  
Confidentiality Notice:  
This document contains information that is confidential and proprietary to Radius Health, Inc. (Radius). 
This document must not be disclosed to anyone other than the study team and internal review committee 
as required. The information in this document cannot be used for any purpose other than the evaluation or conduct of the research without the prior written consent of Radius Health, Inc.  NCT #[STUDY_ID_REMOVED]

Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 2 of 63 
 
 
   
 Confidential   
    1. TABLE OF CONTENTS  
1 TABLE OF CONTENTS  ................................................................... 2  
LIST OF TABLES  ................................................................................................. 4  
LIST OF FIGURES  ............................................................................................... 4  
LIST OF ABBREVIATIONS ................................................................................ 5  
2 PROTOCOL SYNOPSIS  ................................................................... 8  
3 RESPONSIBLE PARTIES ............................................................... 12  
4 VERSION HISTORY  ....................................................................... 13  
5 RESEARCH QUESTIONS, OBJECTIVES, AND ENDPOINTS  ... 14  
5.1 Research Questions  ........................................................................... 14  
5.2 Objectives and Endpoints  ................................................................. 15  
5.3 Justification of Objectives and Endpoints  ........................................ 16  
6 BACKGROUND AND RATIONALE ............................................. 17  
6.1 Disease Background ......................................................................... 17  
6.2 Currently Available Treatment Options  ........................................... 19  
6.2.1  Teriparatide  ....................................................................................... 19  
6.2.2  Romosozumab .................................................................................. 20  
6.2.3  Abaloparatide .................................................................................... 22  
6.3 Study Rationale ................................................................................. 23  
7 RESEARCH MET HODS  ................................................................. 25  
7.1 Study Design ..................................................................................... 25  
7.1.1  Rationale for the Current Study Design ............................................ 28  
7.1.2  Strengths of the Study Design .......................................................... 29  
7.1.3  Limitations of the Study Design  ....................................................... 29  
7.1.4  Generalizability  ................................................................................. 31  
7.2 Setting  ............................................................................................... 31  
7.3 Duration of Subject Participation  ..................................................... 31  
7.4 Study Population ............................................................................... 32  
7.4.1  Subjec t Selection Criteria  ................................................................. 32  
7.4.2  Discussion of Study Population ........................................................ 35  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 3 of 63 
 
 
   
 Confidential   
    7.5 Data Sources  ..................................................................................... 36  
7.6 Variables for Data Extraction  ........................................................... 37  
7.6.1  Demographics and Baseline Variables  ............................................. 37  
7.6.2  Risk Factors ...................................................................................... 38  
7.6.3  Co-morbidities  .................................................................................. 38  
7.6.4  Osteoporosis Treatment History  ....................................................... 39  
7.6.5  Concomitant Medications  ................................................................. 39  
7.6.6  Anabolic Drug Exposure .................................................................. 39  
7.6.7  Outcomes  .......................................................................................... 39  
7.6.7.1  Evaluation of Effectiveness  .............................................................. 40  
7.6.7.2  Evaluation of Cardiovascular Safety  ................................................ 41  
7.7 Data Management  ............................................................................. 41  
7.8 Statistical Methods and Analyses ..................................................... 41  
7.8.1  Power and Sample Size  .................................................................... 42  
7.8.1.1  Sample Size  ...................................................................................... 42  
7.8.1.2  Power Calculation  ............................................................................. 42  
7.8.2  Creation of Analytic Cohorts and Source Data Characteristics ........ 42  
7.8.3  Analysis Populations ........................................................................ 42  
7.8.4  Baseline Descriptive Statistics  .......................................................... 43  
7.8.5  Propensity Score Matching  ............................................................... 43  
7.8.6  Effectiveness Analyses  ..................................................................... 43  
7.8.7  Safety Analyses  ................................................................................ 45  
7.8.8  Anabolic Drug Exposure .................................................................. 45  
7.8.9  Concomitant Use of Osteoporosis Treatment ................................... 46  
7.8.10  Sensitivity Analyses .......................................................................... 46  
7.8.10.1  Population Selection  ......................................................................... 46  
7.8.10.2  Safety Endpoints ............................................................................... 46  
7.8.11  Subgroup Anal yses ........................................................................... 47  
7.8.11.1  Subgroup Analyses for Effectiveness: .............................................. 47  
7.8.11.2  Subgroup Analyses for Safety: ......................................................... 47  
7.9 Quality Assurance  ............................................................................. 48  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 4 of 63 
 
 
   
 Confidential   
    8 PROTECTION OF HUMAN SUBJECTS  ....................................... 49  
9 MANAGEMENT AND REPORTING OF ADVERSE 
EVENTS/ADVERSE REACTIONS  ................................................ 50  
10 PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS  ........................................................................... 51
 
11 REFERENCES  ................................................................................. 52  
12 APPENDICES  .................................................................................. 59  
12.1  Appendix 1: List of Parameters for Propensity Score Matching  ...... 59  
12.2  Appendix 2: Fracture Algorithm  ...................................................... 60  
12.3  Appendix 3: Cardiovascular Event Codes ........................................ 61  
12.4  Appendix 4: Diagnostic Codes for All Comorbidities ..................... 62  
12.5  Appendix 5: National Drug Code (NDC) Codes and HCPCS Codes for the Medications Used  .................................................................. 63
 
 
LIST OF TABLES  
Table 1  Inclusion Criteria .............................................................................. 33  
Table 2  Exclusion Criteria ............................................................................. 34  
Table 3  Metadata About Data Source and Software...................................... 37  
 
LIST OF FIGURES  
Figure 1  Study Design Schematic  ................................................................... 25  
  
  
 

Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 5 of 63 
 
 
   
 Confidential   
    LIST OF ABBREVIATIONS  
Abbreviation  Term  
ABL  Abaloparatide  subcutaneous (abaloparatide -SC; TYMLOS®) 
ACTIVE  Abaloparatide Comparator Trial in Vertebral Endpoints  
ACTIVExtend Abaloparatide Comparator Trial in Vertebral Endpoints extension 
study 
AE Adverse event 
AT As-Treated (analysis)  
AVA  Anabolic Versus Antiresorptive 
BMD  Bone mineral density  
bpm beats per minute  
CCI Charlson Comorbidity Index 
CDC  Centers for Disease Control and Prevention 
CFR  Code of Federal Regulations 
CI Confidence interval  
CMS  Centers for Medicare & Medicaid  Services 
CPT Common Procedural Terminology  
CQ Case qualifying  
CTX C-telopeptides of type 1 collagen crosslinks  
CV Cardiovascular 
EMA  European Medicines Agency  
EU European Union 
FDA  Food and Drug Administration 
GCP  Good Clinical Practice  
CTX C-telopeptides of type 1 collagen crosslinks  
CV Cardiovascular 
CTX  C-telopeptides of type  1 collagen crosslinks  
CV Cardiovascular  
EMA  European Medicines Agency  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 6 of 63 
 
 
   
 Confidential   
    EU European Union 
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HCPCS Healthcare Common Procedure Coding System 
HIPAA  Health Insurance Portability and Accountability Act  
hPTHrP(1-34) First 34 amino acids of human parathyroid hormone-related peptide 
HR Hazard ratio  
HRQoL  Health -related quality of life  
ICD International Classification of Diseases  
ICD-9 International Classification of Diseases, 9th Revision  
ICD9 -CM International Classification of Diseases, 9th Revision , Clinical 
Modification  
ICD10 -CM International Classification of Diseases, 10th Revision , Clinical 
Modification  
ICH International Council on Harmonisation  
ICSR Individual Case Safety Report 
IOF International Osteoporosis Foundation 
IRB Institutional review board  
IRR Incidence rate ratio  
ITT Intention- to-treat (analysis)  
MACE  Major adverse cardiovascular events  
MedDRA  Medical Dictionary for Regulatory Activities  
MI Myocardial infarction  
NDC  National Drug Code 
NOF  National Osteoporosis Foundation  
P1NP  Procollagen type  1 N-terminal propeptide  
PS Propensity score 
PTD  Patient Transactional Dataset  
SAS Statistical Analysis Software  
SC Subcutaneous 
SD Standard deviation 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 7 of 63 
 
 
   
 Confidential   
     
 SmPC  Summary of Product Characteristics 
TPTD  Teriparatide subcutaneous ( Forteo)  
USA  United States of America  
WHO World Health Organization  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 8 of 63 
 
 
   
 Confidential   
    2. PROTOCOL SYNOPSIS  
Title:  
A Retrospective, Observational Cohort Study Evaluating the Effectiveness and 
Cardiovascular Safety of Abaloparatide in Postmenopausal Women New to Anabolic Therapies  
Name of Sponsor: 
Radius Health, Inc. (Radius) 
Reference Drug:  
Teriparatide subcutaneous (TPTD; Forteo®) 
Background and Rationale: Osteoporosis is a highly prevalent systemic skeletal disorder characterized by 
compromised bone strength predisposing individuals to an increased risk of fractures. Anabolic drugs, which can add bone and potentially improve bone microarchitecture, 
have become available as an additional treatment opt ions for individuals with 
osteoporosis . These anabolic drugs include teriparatide ( TPTD ; Forteo: Eli Lilly and 
Co., Indianapolis, IN, USA), a first-in -class anabolic agent that received United States 
of America ( USA)  Food and Drug Administration (FDA) approval in 2002, 
abaloparatide ( ABL ; TYMLOS : Radius Health, Inc., Boston, MA, USA), approved by 
the FDA in 2017 and romosozumab (Romo; Evenity: Amgen  and UCB, Thousand 
Oaks, CA, USA) , a humanized monoclonal antibody with dual action approved by the 
FDA in 2019. The FDA approval of ABL included consideration of results at 
18 months from the landmark ACTIVE trial and the first 6  months of the 
ACTIVExtend trial, which demonstrated consistent significant and rapid reductions in the risk of vertebral and nonvertebral fractures regardless of age, years since menopause, presence or absence of previous fracture, and bone mineral density 
(BMD ). 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 9 of 63 
 
 
   
 Confidential   
    Research Question:  
The purpose of the current study is to evaluate the real -world comparative 
effectiveness and cardiovascular safety of ABL compared with TPTD during the 
18-month period after treatment initiation in propensity score (PS)-matched cohorts .  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 10 of 63 
 
 
   
 Confidential   
    Objectives  and Endpoints: 
Objectives  Endpoints  
Primary Objective:  
• To evaluate the effectiveness of ABL 
for the treatment of osteoporosis in 
postmenopausal women in the real -
world healthcare setting in the USA compared with TPTD using the same cohort of PS-matched patients.  Primary Endpoint: 
• Time to the first incidence of 
nonvertebral fracture (hip, pelvis, 
shoulder, radius or ulna, wrist,  femur, 
tibia or fibula, ankle) within  the 
18 months after treatment initiation.  
Secondary Objective:  
• To evaluate the cardiovascular safety  
of ABL for the treatment of osteoporosis in postmenopausal women in the real -world healthcare 
setting  in the USA compared with 
TPTD using the same cohort of PS-matched patients.  Secondary Endpoints:  
• Time to the first incidence of the 
composite endpoint of nonfatal MI, 
nonfatal stroke, or in -hospital 
cardiovascular death  within the 
18 months after treatment initiation and 
while still on therapy.  
• Time to the first incidence of the composite endpoint of nonfatal MI, nonfatal stroke, heart failure or in-hospital cardiovascular death within the 18 months after treatment initiation and while still on therapy.  
Exploratory Objective: 
• To further evaluate the effectiveness 
and cardiovascular safety of ABL for 
the treatment of osteoporosis in postmenopausa l women in the real -
world healthcare setting  in the USA  
compared with TPTD using the same cohort of PS-matched patients.  Exploratory Endpoints: 
Efficacy  
• Time to the first  incidence of hip 
fracture within  the 18 months after 
treatment initiation.  
Safety  
• Time to the first i ncidence of MI 
• Time to the first i ncidence of stroke 
• Time to the first incidence of -in -
hospital cardiovascular death   
• Time to the first i ncidence of heart 
failure 
 
Study Design:  
This is a retrospective observational cohort study using healthcare administrative 
claims data from the USA . 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 11 of 63 
 
 
   
 Confidential   
    Setting: 
This study will use anonymized patient level  data from PRA’s Symphony Health 
Patient Source Integrated Dataverse (IDV) database. Data are routinely collected in 
healthcare encounters from all available healthcare sites (inpatient hospital, outpatient hospital, physician office, pharmacy, etc.) for all types of provided services including specialty, preventive care, and office-based treatments.  
Study Population: 
Patient Population : 
The patients for inclusion in the study analyses will be identified based on the 
prescribed anabolic therapy filled (ABL or TPTD). The study intake period was chosen to coincide with the date of the FDA approval of ABL  in the USA . 
Data Sources:  
This study will use anonymized patient claims data from the Symphony Health Patient Source IDV database including the enhanced hospital data.  
Study Size:  
This retrospective cohort study is expected to include a total of 16,000 patients; 8000 patient s per treatment cohort  (ABL or  TPTD ). 
Data Analysis: 
Comparison of the time to the first incidence of fracture or cardiovascular  outcomes 
between the PS-matched treatment cohorts will be based on the 2-sided 95% 
confidence interval of hazard ratio between ABL versu s TPTD from a Cox 
proportional hazards model i n both the effectiveness and safety analyses, The Kaplan -
Meier method will be used to estimate event rates. Log rank test p-value will be calculated. All analyses will be based on the index medication cohort  (ABL or TPTD). 
Milestones:  
No interim analys es or reporting are planned . 
 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 12 of 63 
 
 
   
 Confidential   
    3. RESPONSIBLE PARTIES  
This study is sponsored by Radius Health, Inc. 
Contact Information: 
 
 
22 Boston Wharf Road, 7th floor Boston MA 02210 
Telephone:  
Email:  
 

Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 13 of 63 
 
 
   
 Confidential   
    4. VERSION  HISTORY  
Version  
Date  Version 
Number  Change Log  Rationale for Change  
09 July 2021  1.0 Not applicable.  Not applicable.  
 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 14 of 63 
 
 
   
 Confidential   
    5. RESEARCH QUESTIONS , OBJECTIVES , AND 
ENDPOINTS  
5.1. Research Questions  
The purpose of the current study is to evaluate the real -world effectiveness and 
cardiovascular safety of abaloparatide (ABL) compared with teriparatide (TPTD) for the 
treatment of osteoporosis in postmenopausal women  during the 18-month period after 
treatment initiation in propensity score (PS )matched cohorts . 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 15 of 63 
 
 
   
 Confidential   
    5.2. Objectives and Endpoints  
Objectives  Endpoints  
Primary Objective:  
• To evaluate the effectiveness of ABL 
for the treatment of osteoporosis in 
postmenopausal women in the real -
world healthcare setting in the United States of America ( USA) compared 
with TPTD using the same cohort of propensity score (PS)-matched patients.  Primary Endpoint: 
• Time to the first incidence of 
nonvertebral fracture (hip, pelvis, 
shoulder, radius or ulna, wrist, femur, tibia or fibula, ankle) within  the 
18 months after  treatment initiation.  
Secondary Objective:  
• To evaluate the cardiovascular safety  
of ABL for the treatment of osteoporosis in postmenopausal women in the real -world healthcare 
setting in the USA compared with 
TPTD using the same cohort of PS-matched patients.  Secondary Endpoints:  
• Time to the first incidence of the 
composite endpoint of nonfatal MI, 
nonfatal stroke, or in -hospital 
cardiovascular death within the 
18 months after treatment initiation and 
while still on therapy.   
• Time to the first incidence of the composite endpoint of nonfatal MI, nonfatal stroke, heart failure or in-hospital cardiovascular death within the 18 months after treatment initiation and while still on therapy.  
Exploratory Objective: 
• To further evaluate the effectiveness 
and cardiovascular safety of ABL for 
the treatment of osteoporosis in postmenopausal women in the real -
world healthcare setting in the USA compared with TPTD using the same cohort of PS-matched patients.  Exploratory Endpoints: 
Efficacy  
• Time to the first incidence of hip fracture within the 18 months after treatment initiation.  
Safety  
• Time to the first incidence of MI 
• Time to the first incidence of stroke 
• Time to the first incidence of in -
hospital cardiovascular death  
• Time to the first incidence of heart failur e 
 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 16 of 63 
 
 
   
 Confidential   
    5.3. Justification of Objectives  and Endpoints  
Comparative effectiveness  for PS-matched ABL -treated patients versus TPTD -treated 
patients will be evaluated for nonvertebral fracture and hip fracture using a claims -based 
algorithm ( Wright  et al, 2019). Evaluation will be limited to nonvertebral fractures given 
the evidence requirement from regulatory authorities  in the European Union (EU ). Hip 
fractures, an important type of nonvertebral fractures that are associated with a greater 
disease burden including functional decline, loss of independence, and increased  risk of 
mortality , will also be evaluated. Although hip fractures account for 14% of all fractures, 
they constitute 72% of the cost of osteoporotic-related fracture in the US A (Burge  et al, 
2007; Gold  et al, 2019; Kochanek  et al, 2019). The ACTIVE study was not sufficiently 
powered to demonstrate a significant reduction in hip fracture, but an observational study reported a 45% reduction in hip fracture for pat ients treated with TPTD  (Burge  et al, 
2017). Evaluation of vertebral fracture incidence will not be carried out given the limitation of healthcare claims data that would only capture clinical vertebral fractures 
(ie, those corresponding to a healthcare encounter ). Subgroup analyses will be conducted 
based on osteoporosis treatment history, given the variation in response to anabolic 
treatment  by osteoporosis treatment history, and in patients considered to be at high risk 
for fractures. 
Comparative cardiovascular safety for PS -matched ABL -treated patients  versus TPTD -
treated patients  will be evaluated based on time to the first incidence of the composite 
endpoint of nonfatal myocardial infarction ( MI), nonfatal stroke, and in -hospital 
cardiovascular death  within the 18 months after treatment initiation while still on 
therapy. The International Classification of  Diseases, 10th Revision, Clinical 
modification  (ICD-10-CM) codes for MI, stroke, and heart failure from the Food and 
Drug Administration (FDA ) Mini-S entinel database (FDA , 2021) will be used as a guide 
for event identification  with modifications to ensure that relevant endpoints are captured 
(Appendix 4). Published results from a validation study of the MI codes used in the Mini-S entinel database demonstrated a positive predictive value of 86% ( Cutrona  et al, 
2013). For evaluation of mortality, hospital discharge status will be used. It is important to note that hospital claim s do not specify the cause of death nor causal association with a 
specific medication.  A previously validated claim s-based algorithm will be used to derive 
in-hospital cardiovascular death (indirect approach 2, Xie  et al, 2018). Compared to a 
previous ly published fatal MI and stroke method  (Ritchey  et al, 2017), the algorithm we 
adopted has higher sensitivity  while main taining high specificity.  The net reclassification 
index is  improved.    
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 17 of 63 
 
 
   
 Confidential   
    6. BACKGROUND AND RATIONALE  
6.1. Disease Background 
Osteoporosis is a highly prevalent systemic skeletal disorder characterized by low bone 
mineral density (BMD), decreased bone strength, and microarchitectural deterioration of 
bone tissue that leads to enhanced fragility and increased risk of fractures (Rizzoli  et al, 
2001). The fracture s associated with the greatest morbidity and mortality, as well as an 
economic burden to society, together make up the clinically significant and medically 
relevant group termed major osteoporotic fractures. According to the International 
Osteoporosis Foundation (IOF), approximately 10 million Americans have osteoporosis 
and 44 million more have low bone mass (osteopenia) ( IOF, 2020). In the USA , there are 
an estimated 2  million osteoporotic fractures annually ( Litwic et al, 2014). At the age of 
50, a woman in the USA has a lifetime risk of approximately 50% for incurring osteoporotic fractures (Cosman et al, 2014 ). As the population ages, the number of 
osteoporotic fractures is certain to increase in both men and women by more than 3 -fold 
over the next 50 years (World Health Organization  [WHO] 2007). 
One of the major public health problems associated with osteoporosis is its association with low -energy trauma or fragility fractures. Fragility fractures affect up to one-half of 
women and one-third of men over the age of 50 ye ars and are often associated with low 
bone density (Cummings  and Melton, 2002; Ross , 1996; Jones  et al,  1994). Such 
fractures occur most commonly in the hip, spine, and wrist ( Cummings  and Melton , 
2002; Tosteson  et al 2001). Clinical studies have demonstrated that treatment of patients 
with fragility fractures can reduce the risk of future fractures (Delmas , 2002; Hochberg 
2000). Thus, it is important that these patients not only receive treatment  for the 
presenting fracture, but also treatment for the prevention of future fractures (Tosi  and 
Lane, 1998; Rosier 2001). 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 18 of 63 
 
 
   
 Confidential   
    Spinal fractures have also been associated with poor outcomes and high mortality rates 
(Suzuki  et al, 2008). It has been reported that once a patient has sustained a vertebral 
fracture, the risk of a subsequent vertebral fracture increases by > 300% and the risk of a 
subsequent hip fracture increases by 200% (Black  et al , 1999 ). Additional studies have 
shown that almost half of patients with a prior vertebral fracture will experience 
additional vertebral fractures within the next 3 years, many within the first year 
(Robinson et al, 2002 ; Lindsay  et al,  2001 ). Patients who sustained a vertebral body 
fragility fracture had a prolonged course, which can lead to significant disability even 1 year later ( Suzuki  et al, 2008). Patients with a diagnosis of osteoporosis who have 
experienced any fracture have an 86% increase in their risk for another fracture (Kanis  et 
al, 2004). With the severity of these implications, prevention of subsequent fractures has 
become a primary focus from a patient care and societal standpoint.  
Major osteoporotic fractures (those of the wrist, shoulder, hip, and clinical spine) account 
for 94% of the fracture risk for women with low or minimal trauma ( Ensrud et al, 2016). 
Major osteoporotic fractures contribute to accumulated frailty such that the Frai lty Index 
is significantly higher in those elderly women who have experienced a major osteoporotic 
fracture. As a result, these women have worsening frailty and greater morbidity after a 
major osteoporotic fracture ( Li et al, 2016 ). The Frailty Index was associated with a 
predicted increase in the risk of falls, fractures, death , and overnight hospitalizations 
(Li et al,  2014). Consequently, prevention of clinically significant and medically relevant 
major osteoporotic fractures has the potential to reduce health care costs, and reduce the 
risk of falls, fractures, hospitalizations, and death  as well as benefit postmenopausal 
women based on reduced frailty. 
Suffering a major osteoporotic fracture substantially increases the risk of subsequent 
fractures (Burshell  et al,  2010), and this risk is highest in the first few years after a 
fracture. There is strong evidence demonstrating that after hospital discharge, patients with an osteoporotic fracture face higher morbidity, subsequent fractures, and increased mortality ( Nazrun et al, 2014). Of the estimated 2 million annual osteoporotic fractures in 
the US A, the most common fracture site is the distal radius where 640,000 cases were 
reported in 2001 alone (Litwic et al, 2014). These incident fractures represent an event that is associated with a highly elevated risk of a subsequent major osteoporotic fracture within the next 1 to 2 years ( Barrett -Connor et al, 2009 ; Chen et al,  2013 ). Anabolic 
therapy is often recommended for patients at a high risk of future fracture, including patients with recent fracture and patients with multiple fractures, but evidence for rapid 
protection of all -site fractures is lacking.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 19 of 63 
 
 
   
 Confidential   
    Previously, it has been observed that postmenopausal women with osteoporosis have a 
4-fold higher increased risk for cardiovascular events compared with postmenopausal 
women without osteoporosis (Tankó et al, 2005 ). Additionally, Tanko et al reported that 
postmenopausal women with a low BMD value, bone loss, and presence of previous 
fracture have an increased mortality due to cardiovascular causes. The inverse 
relationship between bone mass and coronary heart disease risk in women found in this 
study is supported by reports that postmenopausal women with low BMD values or a greater degree of bone loss have a greater prevalence and severity of a ortic calcification, 
a predictor of cardiovascular disease incidence and mortality. This inverse relationship 
was independent of age, education, smoking, alcohol, systolic blood pressure, lipids, 
diabetes, and menopausal history. The inverse relationship b etween the metacarpal 
cortical area and the incidence of coronary heart disease observed in women might suggest that efforts to reduce the risk of osteoporosis may decrease the risk of coronary 
disease in women ( Samels on et al, 2004). 
6.2. Currently Available Treatment Options  
Treatment options for osteoporosis that are currently available in the EU can be divided into 2 broad categories: 
• Antiresorptives: bisphosphonates and denosumab 
• Anabolic s: TPTD  and romosozumab 
Most of the antiresorptive products provide only a moderate rate of increase in BMD and 
require several years of treatment to reach their fracture reduction benefit. Given that ABL is an anabolic, only ABL and the approved anabolics – TPTD  and romosozumab – 
are discussed further herein.  
6.2.1. Teriparatide  
Teriparatide [rhPTH(1 -34)] is closely related to ABL and among its approved European 
Medicines Agency (EMA) indications is the trea tment of osteoporosis in postmenopausal 
women (and men) at increased risk of fracture. This approval was based on a significant 
reduction in the incidence of vertebral and nonvertebral fractures. 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 20 of 63 
 
 
   
 Confidential   
    Clinical data supporting anabolic the effects of TPTD includ e the demonstration of 
elevated levels of the bone formation marker procollagen type 1 N-terminal propeptide 
(P1NP) and the bone resorption marker C- telopeptides - of type 1 collagen crosslinks  
(CTX) in the Anabolic Versus Antiresorptive (AVA) study in pati ents receiving TPTD  at 
20 µg SC daily (Dempster  et al, 2016). Levels increased significantly starting at 1 and 3 
months, and continued to rise through 6 months, and were greater for P1NP suggesting evidence for a “net anabolic effect”.  
In the AVA study, using quadruple labeling, TPTD  increased from baseline all forms of 
bone formation (modeling, remodeling, and overflow modeling bone formation) in the 
cancellous and endocortical bone envelopes and modeling-based bone formation was 
seen in the periosteum ( Dempster  et al, 2018 ). 
The Summary of Product Characteristics (SmPC) for teriparatide shows that nausea, pain in limb, headache, and dizziness  are the most commonly reported adverse reactions . For 
cardiovascular adverse events  (AEs) , palpitations are noted to be common, but 
tachycardia is uncommon. Orthostatic hypotension is included in the Warnings and Precautions section. Despite the occurrence of these class -effect AEs, there is no 
evidence of an increase in major cardiovascular AEs for TPTD . 
6.2.2. Romosozumab 
Romosozumab, a monoclonal antibody that acts as a sclerostin inhibitor . was approved in 
2019 for the treatment of osteoporosis in postmenopausal women at high risk of fracture. Nonclinical and clinical studies have demonstrated a mixed anabolic/antiresorptive effect on bone. Romosozumab was approved based on the results from 2 randomized controlled 
pivota l studies in 2 different populations with different levels of fracture risk. In the 
ARCH study (Saag  et al, 2017), romosozumab demonstrated a statistically significant 
reduction in fracture rate at 12 months compared with  alendronate, including a reduction 
in the rate of nonvertebral fractures. However, in the placebo-controlled FRAME study (Cosman et al, 2016), while the results were positive for the primary endpoint of new 
vertebral fractures, the rate of improvement of nonvertebral fractures did not reach 
statistical significance.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 21 of 63 
 
 
   
 Confidential   
    Clinical data supporting the anabolic effects of romosozumab include demonstration of a 
rapid increase in bone formation demonstrated by P1NP levels peaking at 1 month, but 
then declining to the baseline level by Month 6 in both the FRAME and ARCH studies. In addition, there was evidence of suppression of bone resorption, as CTX levels rapidly decreased by 50% from baseline at 1 month and remained at that level throughout the 
remaining 12 months of treatment.  
The histomorphometry completed on patients in the FRAME study at 2 months after quadruple label staining demonstrated a doubling from baseline of dynamic bone formation indices but bone resorption was halved suggesting this initial gain was 
modelling based; biopsies at 12 months showed that the parameters of dynamic bone 
formation were decreased; there was no significant evidence for cortical porosity (Chavassieux et al, 2019). 
In the SmPC, the use of romosozumab is contraindicated in patients with a history of MI 
or stroke. In randomized controlled clinical studies, an increase in serious cardiovascular 
events (MI and stroke) was observed in subjects treated with romosozumab compared with control subjects.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 22 of 63 
 
 
   
 Confidential   
    6.2.3. Abaloparatide 
Abaloparatide is a chemically synthesized analog of the first 34  amino acids of human 
parathyroid hormone-related peptide [hPTHrP(1 -34)] that is anabolic in bone. Secondary 
pharmacological effects of ABL include transient and reversible increases in heart rate 
after injection, with associated AEs of palpitations and tachycardia observed in the 
pivotal clinical study. A post-hoc analysis was performed to examine th e effects of 
treatment on heart rate, blood pressure, and cardiovascular -related AEs, including MACE 
with or without heart failure in the ACTIVE/ACTIVExtend study ( Cosman et al, 2020). 
ABL and TPTD  transiently increased heart rate relative to placebo.  After the first dose, 
the mean (SD) change in heart rate from before treatment to 1  hour after treatment was 
7.9 (8.5) bpm for ABL , 5.3 (7.5) bpm for TPTD , and 1.2 (7.1) bpm for placebo. A similar 
pattern was observed over subsequent visits. The corresponding change in mean supine 
systolic and diastolic blood pressure 1 hour after treatment was -2.7/-3.6 mmHg for ABL , -2.0/-3.6 mmHg for TPTD , and -1.5/-2.3 mmHg for placebo. The percentage of 
participants with serious cardiac AEs was similar across the treatment groups (0.9% and 
1.0%). In a post-hoc analysis, the percentage of participants with MACE during the ACTIVE study was 0.5% in the ABL group, 0.6% in the TPTD  group, and 1.2% in the 
placebo group; MACE + heart failure increased the proportion in the placebo group to 
1.7%. Time- to-first incidence of MACE + heart failure was significantly longer for ABL  
compared with placebo (p = 0.02) and for TPTD  compared with placebo (p = 0.04 ; 
Cosm an et al, 2020). During the 2-year ACTIVExtend period, the incidence of MACE , 
with or without heart failure, was similar between the placebo/alendronate and 
ABL /alendronate groups l eading to the conclusion that ABL was associated with 
transient increases in heart rate and small decreases in blood pressure in postmenopausal 
women with osteoporosis, with no increase in risk of serious cardiac AEs, MACE, or 
heart failure. 
No published e pidemiological studies have examined the cardiovascular risk associated 
with transitory, intermittent increases in heart rate due to an external intervention, as is 
the case with ABL administration, in the general population and in the target population of postmenopausal women. A review of data on the long-term effects of TPTD , which 
has a similar mechanism of action to ABL , and whose administration is associated with a 
similar (although slightly less pronounced) increase in heart rate, follow-up study of the Fracture Prevention Trial of TPTD  versu s placebo (N = 1262), did not show a discernible 
increase in cardiovascular disease after 5  years (Tashjian  et al, 2006 ; Prince  et al, 2005). 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 23 of 63 
 
 
   
 Confidential   
    6.3. Study Rationale  
Currently, no published studies on the comparative effectiveness or cardiovascular safety 
of ABL versus TPTD in a real -world setting are available (Fuggle  et al, 2020). There are 
also no real-wo rld data on the cardiovascular safety of these osteoanabolic agents  in this 
patient population . In an earlier study, Radius used data from claims and electronic 
medical records to characterize patients new to ABL relative to patients new to  TPTD . 
Results from that study were previously reported and the differences in patient characteristics in the real -world setting were noted when compared with the 
characteristics of patients in clinical stud ies (Imel  et al, 2020). Furthermore, patients new 
to ABL  treatment were similar in their disease characteristics to patients on  TPTD . This 
observation reflects comparable market access to the 2 anabolic therapies in addition to an equivalence in prescribing recommendation s based on clinical practice guidelines 
(Camacho  et al, 2020). 
Previously, Radius completed an analysis of Symphony Health Patient Source administrative claims data for evaluation of the market dynamics  for osteoporosis 
treatments  (Williams  et al, 2019). The purpose of that study was to characterize patients 
new to anabolic treatment in the real -world setting and to evaluate incidence of fractures 
following treatment initiation . Baseline cardiovascular risk factors (ie, dyslipidemia, 
hypertension, diabetes, and obesity), disease history  and cardiovascular events before and 
after treatment initiation were evaluated as exploratory analys es. Because t he study 
started shortly after the launch  of ABL (TYMLOS) , limited longitudin al data were 
available to assess impact of treatment on fracture outcomes . Furthermore, the data 
capture rate for inpat ient events was  low (only 25% of inpatient events were captured). 
The current protocol incorporates the recommendations received from several national 
scientific advisory meetings in the EU to expand data scope and further evaluate the real-
world comparative effectiveness and comparative cardiovascular safety of ABL versus 
TPTD. First, additional real -world data have been accumulated leading to a larger 
number of evaluable patients with a longer longitudinal data availability. Second, we 
have secured access to the enhanced hospital data through PRA Health Sciences, which 
provide access to 60% of inpatient events. Furthermore, mortality  data , which were 
previously not available, can now be determined using hospital discharge records. A validated car diovascular mortality  algorithm (Xie et al, 2018) will be used to derive in-
hospital cardiovascular mortality  Both in- hospital cardiovascular mortality and all-causes 
mortality will be included.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 24 of 63 
 
 
   
 Confidential   
    The purpose of the current study is to evaluate the real -wor ld comparative effectiveness 
and comparative cardiovascular safety of ABL versus TPTD during the 18-month period 
after treatment initiation in PS  matched cohorts.  
This study will be conducted by PRA Health Sciences using this prespecified protocol and statistical analysis plan.  In the absence of randomization, this observational study 
will use propensity  score (PS) matching for comparative evaluation of safety in addition 
to effectiveness outcomes.  Further quality control work has been perform ed on the data 
including the assignment of codes. The study has reasonable power to show comparable 
effectiveness and safety profile between the 2 active treatment arms.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 25 of 63 
 
 
   
 Confidential   
    7. RESEARCH METHODS  
7.1. Study Design 
This will be a retrospective observational study using admini strative data for the period 
from May 2012 to January 2021. The most recently available data at the time of data 
extraction will be used.  This study will use anonymized patient claims data from PRA’s 
Symphony Health Patient Source Integrated Dataverse (IDV ) database with the inclusion 
of enhanced hospital data, which are claims and remittance from the inpatient hospital 
setting and proprietary Patient Transactional Dataset (PTD) claims and prescription data, 
to apply the inclusion/exclusion criteria for patient selection (see Section  7.4.1) to form 
the data set.  
Figure 1 Study Design Schematic 
 
ABL=  abaloparatide; TPTD  = teriparatide.  
The Identification Period  is the period of time during which subjects will be identified based on their index date 
(01 May 2017 to 30 June 2019).  
The Index Date  is the date on which the subject filed their first claim for a prescription for either ABL or TPTD during 
the identification period.  
The Pre-index Period consists of the 5 years  before the Index Date during which medical history was available for the 
subject.  
The Post-index Treatment Period  consists of the 18 months plus 30 days follow -up after the initiation of treatment 
with anabolic drug (ABL or TPTD) on the index date  and continuing for the duration of treatment. 
Treatment Cohorts  
This is a real -world observational study. Treatments will not be assigned. Instead, cohorts 
are defined as  follows: 
• Abaloparatide Cohort: Patients who filled ≥  1 prescription for ABL  (TYMLOS) 
as their index medication  during the identification period. 

Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 26 of 63 
 
 
   
 Confidential   
    • Teriparatide Cohort: Patients who filled ≥  1 prescription for TPTD  (Forteo) as 
their index medication  during the identification period. 
Evaluation Period  
The date of the first claim for either ABL or TPTD during the identification period 
(between May 1, 2017 and June 30, 2019) will be considered the index date. 
• The medication received on the index date will be considered the index 
medication.  
• Treatment duration may continue for up to 18 months (540 days) after the index 
date.  
• The evaluation of outcomes will start immediately after treatment initiation and will continue for 18 months after the index date for both effectiveness and 
cardiovascular safety evaluation regardless of the drug possession gap between 
any 2 prescription fills.  
Primary Analyses  
• The primary eff ectiveness  analysis will be an Intention -to-Treat (ITT) analysis.  
• The primary safety analysis will be an A s-Treated (AT) analysis.  
Estimated  Sample Size  
Between May 2017 and Ju ne 2019, a total of 16,482 unique female patients ≥  50 years of 
age treated with ABL and 45,350 unique patients ≥  50 years of age treated with TPTD  
have been identified in the Symphony database. After applying inclusion /exclusion 
criteria, t he final number of patients will be determined through PS matching. Based on 
previous studies, it is estimated that approximately 8,000 matched patients will be 
included in each cohort. 
 
 

Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 27 of 63 
 
   
 Confidential   
    

Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 28 of 63 
 
   
 Confidential   
    7.1.1. R
ationale for the Current Study Design 
Currently, there are no published studies on the effectiveness of ABL in the real -world 
setting. Furthermore, neither the comparative effectiveness nor comparative safety of 
ABL versus TPTD have been previously reported. In addition to clinical outcomes evaluated in randomized controlled studies, real-world effectiveness data are important in 
guiding treatment decisions. An evaluation of real-world effectiveness will provide data on a broader population of patients beyond the patient population included in the ACTIVE trial.  Romosozumab is excluded from this study because of its ass ociation with 
an increased risk of cardiovascular events.  

Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 29 of 63 
 
 
   
 Confidential   
    7.1.2. Strengths of the Study Design  
The methodology for the current study design has several strengths: 
• Data are from multiple payers and geographically diverse settings across the 
USA, and the PRA IDV data captures over 90% of pharmacy claims in the USA. 
The prescription claims are for prescriptions filled not just prescription s written. 
As such , the findings from the study are expected to have a high generalizability . 
• A claims -based algorithm, which has a high specificity and has been shown to 
have over 90% accuracy in previous studies , will be used  (Wright  et al, 2019). 
• Although this is not a randomized study, PS-matching will be used to define study cohorts and provide confidence that the 2 cohorts were comparable in their 
probability to receive and benefit from treatment. Patients will be matched on all 
indicators of disease severity and fracture risk, including fracture and treatment history as per evidence-based clinical practice guidelines (Camacho et al., 2020) . 
Furthermore, patients will also be matched on conditions associated with 
increased risk of fall and the requirement for treatments associated with poor bone 
health or quality.  
7.1.3. Limitations of the Study Design 
There are several limitations associated with the design of the current study: 
• The data source is administrative claims data, which are not collected for research purposes. Administrative claims data have inherent limitations including coding errors, inconsistencies, underestimation, overestimation, or incomplete diagnoses data. Th e current study, however, will use a claims -based algorithm to identify 
case qualifying (CQ) fragility fractures associated with osteoporosis. Furthermore, any misclassification of fractures is nondifferential between the treatment groups being compared an d should not affect the results. 
• Claims -based studies include potential inaccuracies related to the use of 
prescription medications. The prescription claim is for the date of first fill and not the date of first use of the medication, so the assumption is that these are the same date. 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 30 of 63 
 
 
   
 Confidential   
    • Detailed clinical data such as BMD T-scores or the presence of other risk factors 
(eg, family history, smoking status, alcohol intake) associated with disease severity and increased future fracture risk are not available and , therefore, no 
adjustments have been made for these factors. 
• Only death s recorded on the hospital discharge status are  available for the 
derivation of cardiovascular  death in this study. The current study, however, will 
use a claims -based algorithm to identify deaths that are likely to be caused by 
cardiovascular events.  Furthermore, any misclassification of deaths is 
nondifferential between the treatment groups being compared and should not bias the results.  
The comparative evaluation of treatment  options is ideally done within the controlled 
clinical study setting. The current study is observational, and treatments are not assigned. 
As such, randomization is not possible. Although this i s not a randomized study, PS 
matching will be used to define the study cohorts and provide confidence that the 2 treatment groups are comparable in their probability to receive and benefit from 
treatment. P atients will be matched on all indicators of disease severity and fracture risk 
including prior disease and treatment history. Furthermore, patients will also be matched 
on history of falls as well as comorbid conditions and concomitant medications associated with increased fall risk or with bone quality and strength. While several 
comorbidities were initially considered, some measures were ultimately not included in 
the end due to lack of available data. This includes duodenitis. Lastly , there could be 
residual confounding despite matching. The study is planned as an intention -to-treat 
(ITT) analysis for effectiveness evaluation and as -treated ( AT) analysis  for safety 
evaluation with additional consideration for duration of treatment exposure using sensitivity analyses on various length of observed treatment duration for the study 
cohorts. Interpretation is limited by the variable length of follow -up. 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 31 of 63 
 
 
   
 Confidential   
    7.1.4. Generalizability  
All patients will be required to have a total of 12 months of  pre-index medical and 
prescription data. This may result in a study population that is less healthy with a higher 
incidence of fracture compared with that reported in ACTIVE. Regardless, this selection 
bias is not likely to differentially affect the 2  treatment cohorts. Results of the study are 
expected to be generalizable to the population of managed care enrollees including 
commercial and Medicare Advantage members. Regardless of this limitation, the data are 
representative of a broad population of patients from multiple payers and are geographically diverse across the USA . The study will  provide additional information on 
real-world use and outcomes in patients new to treatment with ABL outside of the 
clinical study setting. 
7.2. Setting  
This study will use anonymized patient claims data from PRA ( Symphony Health) IDV 
database. Data are routinely collected in healthcare encounters from all available 
healthcare sites (inpatient hospital, outpatient hospital, physician ’s office, etc.) for all 
types of provided services including specialty, preventive care, and office-based treatments.  
The rationale for the study population and the generalizability of the results of these analyses to the general population of postmenopausal women with osteoporosis are discussed in Section  7.4.2. 
This is a retrospective observational study evaluating real -world data and, therefore, there 
are no assigned study visits. The study uses a convenience sample.  Patients in the 
Symphony database who meet the study inclusion/exclusion criteria ( Table 1 and 
Table 2) will be included in the analyses.  
7.3. Duration of Subject Participation  
Because this is a retrospective claims -based cohort study, subjects included in the 
analyses will not actively participate in the study and no study visits will be required. The study will use anonymized patient data.  
Both effectiveness and cardiovascular safety outcomes will be assessed for patients with 18 months of follow-up data from their index date.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 32 of 63 
 
 
   
 Confidential   
    7.4. Study Population 
7.4.1. Subject Selection Criteria  
Table 1details the inclusion criteria and  Table 2 provides the exclusion criteria for this 
study. 
 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 33 of 63 
 
   
 Confidential    Table 1 Inclusion Criteria  
Criterion  Details  Order of 
Application  Assessment 
Window Code Type  Diagnosis 
Position Applied to 
Study 
Populations  Varied for 
Sensitivity  Source for 
Algorithm 
Women  Sex female Before 
selection of the index date  Any time  NA NA Yes No NA 
Age: ≥  50 years  ≥ 50 years of age  Before selection of  the 
index date  [0, 0]  NA NA Yes No Proxy for 
postmenopausal 
≥1 prescription fill 
for ABL or TPTD  between May 1, 2017 and June 
30, 2019 
(identification period) Will determine 
the index date  May 1, 2017 
and June 30, 2019 NDC  NA Yes Yes. Further 
restriction on 
various 
duration of treatment  NA 
≥ 1 claim for 
medical or hospital 
visit and a 
pharmacy claim  in the 12  months 
before the index 
date Before selection of the index date  0-12 months 
pre-index NDC , ICD , 
HCPCS  Any Yes Yes PRA proprietary 
algorithm to 
determine coverage 
ABL  = abaloparatide; NA= not applicable; NDC  = National Drug Code; post -index = after the index date; pre -index = before the index treatment date; 
TPTD  = teriparatide.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 34 of 63 
 
   
 Confidential    Table 2 Exclusion Criteria  
Criterion  Details  Assessment 
Window Code Type  Diagnosis 
Position Applied to 
Study 
Populations  Varied for 
Sensitivity  Source for 
Algorithm 
Paget’s disease  Presence of ≥ 1 claim 
for Paget’s disease Pre-index ICD Any  Yes No NA 
Malignancy  Presence of ≥ 1 claim  
except for 
nonmelanoma skin 
cancers, carcinoma in -
situ of the cervix, ductal carcinoma in -
situ of breast  Pre-index ICD Any Yes No 
NA 
Indicators of high disease burden and high risk of death  CCI >  10  Pre-index ICD Any Yes No NA 
With  prior index 
anabolic treatment  Anabolic treatment includes ABL , TPTD  
and romosozumab Pre-index NDC  and 
HCPCS  NA Yes No NA 
Switch to a different 
anabolic treatment 
after index  Anabolic treatment includes ABL , TPTD  
and romosozumab Index- date to 18 
months after NDC  and 
HCPCS  NA Yes No NA 
CCI = Charlson Comorbidity Index; ICD  = International Classification of Diseases; NA=  not applicable; pre -index = before the index treatment date; post -index 
= after the index date.  
 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 35 of 63 
 
 Confidential  
 7.4.2. Discussion of Study Population 
The study eligibility criteria are in alignment with the prescribing information in the FDA 
approved labels for both ABL and TPTD and include women with postmenopausal 
osteoporosis. Patients with secondary osteoporosis, Paget’s disease, as well as those who 
would not be candidates for the anabolic drug due to high morbidity burden or high risk of mortality (ie, malignancies), are excluded. Patients with prior alendronate therapy will 
be included because almost half of the population of patients new to anabolic therapies 
have previously used bisphosphonates . Although the treatment guidelines suggest 
initiation of therapy with bone building agents followed by antiresorptive agents to maintain bone, market access criteria requiring step therapy and prior authorization fo r 
anabolic agents result in the use of anabolic agents later in the course of disease progression and severity (McClung et al, 2017; Tsourdi  et al, 2017; Zanchetta et al, 
2018). Limiting the study population to those without any prior therapy would significantly reduce the size of the study population. Therefore, subgroup analyses will be 
performed based on prior use of osteoporosis treatment. Furthermore, there is no 
evidence indicating diminished treatment response to anabolic therapy following alendronate use (Cosman et al, 2017; Langdahl  et al, 2018). As such the study criteria 
provide a suitable population for evaluation of the effectiveness and cardiovascular safety 
of ABL without compromising sample size yet minimizing potential selection biases . 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 36 of 63 
 
 Confidential  
 7.5. Data Sources  
This study will use anonymized patient level  data from PRA ’s Symphony Health IDV  
database, including the enhanced hospital data.  PRA’s IDV database is a large nationally 
representative claims -based database. The database cross -sectionally covers over 80% of 
the population in the USA (approximately 300 million lives) annually. It includes claims 
submitted to all payer types, includin g commercial plans, Medicare, and Medicaid. In 
terms of the pharmacy claims, it captures approximately 92% of the retail and 65% 
specialty pharmacy claims, and approximately 68% of mail order  claim s. For medical 
claims, it covers approximately 60% of profe ssional claims in an outpatient setting. 
Medical claims are open unadjudicated claims.  Mortality data recorded on the hospital 
(medical facility) discharge status covers about 1/3 of the total death records According to National Center for Health Statistics data published on CDC wonder (CDC , 2021), 
35% total deaths in 2019 happened at medical facility which includes hospital inpatient, outpatient or emergency room, death on arrival or unknow status. This number is slightly high (37%) for cardiovascular death (cause of death is I00 to I99 in ICD-10). For women at age 50, 54% percentage of cardiovascular death occurred in medical facilities . The data 
are de-identified, in compliance with Health Insurance Portability and Accountability Act (HIPAA)  guidelines , with stable unique identifier s to allow for longitudinal tracking over 
time.  The terms of the Research Exception provisions of the Privacy Rule, 45 Code of 
Federal Regulations (CFR) Part  164.514(e) exempts Institutional Review Board (IRB) 
approval for this nonexperimental study, which is fully HIPAA compliant.  
Table 3 summarizes the calendar time range used to ascertain cohort entry (index date), as well as the calendar time range of data available for pre-index - assessment windows 
and post-index follow up (study period). The data source name and version are identified, 
as well as any sampling criteria applied (for example, the data cut only includes patients 
with a diagnosis of diabetes). If data linkage is involved, provide a citation or an 
appendix with description of the linkage (how, performance characteristics).  
All individual data will be de-identified and signed data license agreements will be in 
place for  all data sources.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 37 of 63 
 
 Confidential  
 Table 3 Metadata About Data Source and Software 
Data Sources:  PRA (Symphony Health’s) Integrated Dataverse (IDV) database.  
Study Period:  May 1, 2012 to January 31, 2021  
Eligible Cohort Entry 
Period:  May 1, 2017 to June 30, 2019  
Data Extraction 
Date/Version:  June – 2021 via a sin gle data pull  
Data Sampling/ Extraction 
Criteria:  Refer to Section 7:  Research Methods  for study design, treatment 
cohorts, evaluation periods, and subject selection criteria.  
Types of Data:  Medical, hospital and prescription claims data.  
Data Linkage:  No data linkage will be required.  
Data Conversion:  No data conversion will be required.  
Software to Create Study 
Population:   software used to connect to the 
Cl
oudera Hadoop CDH 7.1.4- 1 database for data extraction.  R software 
might be used for propensity score matching.  
 
7.6. Variables for Data Extract ion 
The endpoints to be assessed in this study are provided in Section  5.2. 
7.6.1. Demographics and Baseline Variables  
Potential confounding variables include the following:  
• Demographic variables (age, race/ethnicity  if available) 
• Insurance information (commercial, Medicare, Other) 
• Patient geographic region  (majority coverage includes West, South, Northe ast, 
and Mid west) 
• ABL and TPTD prescriber physician’s specialty (endocrinology, rheumatology, 
surgery, family medicine, internal medicine, nursing related, o bstetric 
• Index date year quarter   

Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 38 of 63 
 
 Confidential  
 7.6.2. Risk Factors  
Conditions associated with increased risk of fractures or falls (Camacho  et al, 2020), 
including pre-index fracture history, for which data are available in administrative claims, 
will be assessed by the presence of ICD codes in the claims database. History of co-morbidities associated with an increased risk of falls and/or fractures, as well as those 
conditions associated with poor bone health, will be assessed  (see Section  7.6.3 for the 
list of co -morbidities).  
Data for m edical  history associated with a high risk of cardiovascular events  will also be 
extracted: MI, stroke, and heart failure.  
7.6.3. Co-morbidities  
Known co-morbidities identified in the target patient population that will be included in 
this retrospective cohort study are:  
• Comorbidities that increase the risk of fall:  prior history of any stroke, mobility 
impairments, vision impairments, hearing impairments, Parkinson’s disease, muscle atrophy, muscle weakness, or sarcopenia.  
• Comorbidities that lengthen healing time: diabetes, liver disease, or renal 
disease.  
• Other comorbidities associated with an increased risk of fractures or requiring treatment associated with an increased fracture risk:  hypertension, 
dyslipidemia, arthritis, respiratory diseases including asthma and chronic 
obstructive pulmonary disease, depression, anxiety, sleep disorders, cardiovascular disease, hypothyroidism, obesity, or gastrointestinal disorders.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 39 of 63 
 
 Confidential  
 7.6.4. Osteoporosis Treatment History  
Pharmacy claim for previous use of any of the following medications: 
• Bisphosphonates (ie, alendronate, ibandronate, risedronate, or zoledronate) 
• Denosumab 
• Oral glucocorticoid s 
• Hormone replacement therapy  
7.6.5. Concomitant Medications 
Concomitant osteoporosis medic ations expected to be used in the target patient 
population include the following: 
• Bisphosphonates (ie, alendronate, ibandronate, risedronate, zoledronate) 
• Denosumab 
• Hormone replacement therapy  
7.6.6. Anabolic Drug Exposure  
Cohort anabolic drug exposure is defined as a prescription filled for either abaloparatide 
(ABL cohort) or teriparatide (TPTD cohort). Exposure will be determined using 
pharmacy claims data in the NDC Codes and HCPCS Codes for Medications. For a list of 
codes please see Appendix 5. 
7.6.7. Outcomes 
Both effectiveness and cardiovascular safety outcomes will be assessed for patients with 
18 months of follow-up data after their index date.  Cardiovascular safety outcomes will 
be evaluated during the treatment period which is from index date to the last prescription anabolic drug possessed within the 18 months after the index date, regardless of the 
anabolic drug possession gap between any 2 prescription fills.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 40 of 63 
 
 Confidential  
 7.6.7.1. Evaluation of Effectiveness 
A claims -based  algorithm with high specificity for fracture site developed by Wright et al 
(Wright et al, 2019) will be used to identify osteoporosis-related fractures  (see 
Appendix 2). Case qualifying (CQ) fractures are those identified during an inpatient 
hospital stay, in any position on the medical claim, or in an outpatient setting accompanied by a fracture repair procedure code. Validation of this algorithm was done 
using International Classification of Diseases, 9th Revision (ICD-9) codes before the 
Healthcare System in the USA switched to the ICD -10 system. In a separate study, 
Wright et al mapped the ICD -9 codes to ICD-10 codes in an evaluation of hip fracture 
trends in the Medicare data. The results from that study did not suggest that the ICD -10 
version systematically identified a higher or lower number of fractures than the ICD -9 
codes.  
The evaluation period for nonvertebral fracture events will start from the index date (date 
of initial prescription dispensed) to the earliest of the followin g events:  
a) First non-vertebral fracture event date (hip, pelvis, shoulder, radius or ulna, wrist, 
femur, tibia or fibula, ankle)  
b) 18 months after the index date 
c) In-hospital death  
The evaluation period for hip fracture events will start from the index date (d ate of initial 
prescription dispensed) to the earliest of the following events:  
a) first hip fracture event date  
b) 18 months after index date 
c) In-hospital death  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 41 of 63 
 
 Confidential  
 7.6.7.2. Evaluation of Cardiovascular Safety 
Evaluation of cardiovascular safety outcomes will be carried out for patients who have 
18 months of follow-up data from their index date while on treatment with ABL or 
TPTD.  The following data variables will be extracted:  
• End of treatment date which is the last pres cription date + supply day 
• Date of the first incidence of  MI 
• Date of the first incidence of  stroke 
• Date of the first incidence of  heart failure 
• Date of in-hospital cardiovascular death  
• Date of all -cause in -hospital death  
7.7. Data Management  
For this study there will be no new p rimary data collected . The study will be conducted 
using real -world (secondary) data for analysis.  software 
will be used to connect to the Cloudera Hadoop (CDH) 7.1.4-1 database for data 
extraction . R software may be used  for PS matching . Datasets and tables, figures, and 
listings (TFLs ) will be created on a Citrix Windows platform using SAS V9.4 M6. 
7.8. Statistical  Methods and Analyses  
The study will use a convenience sample of patients who meet the study selection 
criteria. Medical and pharmacy claims will be used to determine the presence of conditions. International Classification of Diseases Clinical Modification, 9th Revision (ICD-9-CM) and 10th Revision (ICD-10-CM) codes will be used to assess comorbidities.  
National Drug Code (NDC) codes will be used to identify the anabolic drug (ABL or TPTD) and to identify prior and concomitant medications. Additionally, the Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) will be used to support the derivation.  
Detailed code lists are included in Fracture Algorithm (Appendix 2), Cardiovascular Event Codes (Appendix 3), Diagnostic Codes for All Comorbidities (Appendix 4), and NDC Codes and HCPCS Codes for M edications (Appendix 5). 

Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 42 of 63 
 
 Confidential  
 7.8.1. Power and Sample Size  
7.8.1.1. Sample Size  
All patients who meet the inclusion criteria and do not meet any of the exclusion criteria 
will be included in the analysis. After PS matching, it is estimated that approximately 
16,000 patients will be included in the analyses, 8,000 patients in each cohort. 
7.8.1.2. Power Calculation  
• Abaloparatide versus teriparatide with a noninferiority margin of 30%  
o Assuming a nonvertebral fracture rate of 3.5% at the end of 18 months 
o 8,000 matched subjects i n each group 
o 95% power for HR up to 1.3 
7.8.2. Creation of Analytic Cohorts and Source Data Characteristics 
A flow diagram will be provided to reflect the order of operations used to create the 
analytic cohort from the source database. Temporality of assessment w indows will be 
provided relative to the cohort entry (index date) including additional data to denote exclusion/inclusion criteria and how the final sample was derived.  
A table about the source of data (pharmacy claims, medical claims, enhanced hospital claims)  will be provided. The table will include calendar time cohort entry (index date) 
and calendar time range of available data in the pre-index and post- index assessment 
windows. 
7.8.3. Analysis Populations  
Analysis population are all patients meeting the study  inclusion/exclusion criteria and 
selected  after propensity matching. The same matched population will used for both 
effectiveness and safety analysis.    
The effectiveness evaluation will be conducted using an ITT analysis, meaning that the 
first fracture event during the 18 months (+ 30 days follow-up) after the index date will 
be summarized regardless of when treatment ended. Cardiovascular safety outcomes will be evaluated using an As -Treated (AT) analysis based on only events occurring during 
the treatment period which is from the index date to the last prescription anabolic drug obtained within the 18  months after the index date, regardless of the anabolic drug 
possession gap between any 2 prescription fills.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 43 of 63 
 
 Confidential  
 7.8.4. Baseline Descriptive Statistics  
Summary statistics will be provided for all demographic and clinical characteristics  
(Section  7.6.1) for both before and after PS match ing of patients to  the 2 treatment 
cohorts (ABL and TPTD). (S ee Appendix 4 for the list of baseline comorbidities, prior 
medications, previous fractures, fall risk, and prior cardiovascular risks.) Numbers and 
percentages will be provided for dichotomous and polychotomous variables. Means, 
medians, standard deviations, will be provided for continuous variables. 
7.8.5. Propensity Score Matching  
In the absence of rando mization, logistic regression -based PS matching will be used to 
create the analytic cohorts from all patients meeting the study inclusion/exclusion criteria. 
A greedy matching algorithm with no replacement will be adopted. The default caliper, 
the number of standard deviations of the distance measure within which to draw control 
unit, will be set at 0.20 ( Austin  et al, 2011 ). Additional sensitivity analyses using a tighter 
(0.15) or wider (0.3) caliper will be carried out. Cohorts will be prospectively specified to match on age, prior fracture history, osteoporosis-related hospitalization, and chronic 
comorbidities and concomitant medications during the pre-index period that are 
associated with an increased fall risk  (see Appendix 1 for the full list of matching 
variables) . The R software M atchIt package (https://cran.r -
project.org/web/packages/MatchIt/MatchIt.pdf ) will be used to find matched pairs. 
Pre-match  and post-match will be evaluated using prespecified  criteria for mean standard 
difference to ensure that PS matching was successful . After matching , the mean standard 
difference on each covariate between ABL and TPTD is expected to be <  0.10. 
7.8.6. Effectiveness Analyses 
In this study, the primary analyses of effectiveness will be noninferiority analyses for 
ABL  versus TPTD  on time to the first incidence of nonvertebral fractures with a margin 
of 30%. Noninferiority of ABL  to TPTD  will be concluded if the upper bound of 2-sided 
95% CI of HR  between ABL  versus TPTD  is < 1.3. 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 44 of 63 
 
 Confidential  
 In a recent ly published historical control observational study evaluat ing the real -world 
effectiveness of osteoporosis therapies using Medicare claim data between 2008 and 
2011, the fracture incidence rates for the 12 -month pre-treatment period were compared 
with the 12 -month on-treatment period (Yusuf et al, 2018). F or patients treated with 
TPTD, the inci dence rate ratio (IRR [95% CI]) was 0.36 (0.31 to 0.41) for any fracture 
and 0.34 (0.32 to 0.36) for hip fracture. Based on the EMA and FDA noninferiority 
margin guidelines  (EMA , 2005; FDA , 2016), if the upper boundary of ABL versus TPTD 
is HR <  1.3, then ABL will preserve approximately  70% of the TPTD benefit, which is 
higher than the minimum required threshold  of 50%.  
Comparisons of the time to fracture between the PS -matched ABL  and TPTD  groups will 
be based on a Cox proportional hazards model. The hazard ratio (HR) and 95% confidence interval (CI) between the 2  treatment groups will be calculated . The Kaplan -
Meier method will be used to estimate event rates. Log rank test will be calculated.  
For the fracture outcomes, and the corresponding sensitivity and subgroup analyses, patients will be followed for up to 18  months or until their first fracture event (for the 
fracture site of interest under evaluation), whichever comes first. All analyses are based on index medication cohort.  
The duration, in days, from the date of the first filled prescription for ABL or TPTD to the first incidence of nonvertebral fracture will be derived. If a patient does not experience any nonvertebral fractures during the 18 months of tr eatment +  30-day 
follow--up (for a total of 19 months), the patient will be censored at the day of in-hospital 
death or the 19 months. 
For the fracture outcomes, an ITT analysis will be applied . Patients will be followed for 
up to 18 months + 30-day follow-up, or until their first fracture event (for the fracture site 
of interest under evaluation) or in -hospital death, whichever comes first. Duration, in 
days, from the index date to the last follow -up date will be calculated. For calculation 
purposes, 1 month is equivalent to 30 days. All analyses are based on the patient’s index medication cohort.  
A nonvertebral fracture is any fragility fracture at the hip, pelvis, femur, ankle, shoulder  
(including shoulder, humerus, clavicle), radius/ulna, wrist , or tibia/fibula . Derivation 
details are provided in Appendix 2. 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 45 of 63 
 
 Confidential  
 The time to the first incidence of hip fracture and the other 7 individual fracture sites will 
be summarized using similar methods as those used for nonvertebral fracture. 
The Kaplan -Meier curves will be generated to graphically display the fracture event or 
18 months plus 30-day follow-up. 
7.8.7. Safety Analyses 
A Cox proportional hazards model will be used for the time to first cardiovascular event. 
HR and 95% CIs will be presented. 
The ICD-10 diagnosis from the hospital claim and physician claim will be used to derive 
post-index myocardial infarction (MI) (I21.x, I22.x), stroke (I61.x – I63.x), or heart failure (I50.x, excluding I50.x2, I50.8x). Hospital discharge status code (20 to  29 or  40 to 
42) will be derived for in-hospital death. A detailed code list is provided in Appendix 3. 
Subjects with in -hospital cardiovascular  death deriv ed from indir ect approach 2 (Xie  et 
al, 2018) will be included in the analyses . 2018 ICD-10 CM and General Equivalence 
Mappings (GEMS) from the Centers for Medicare & Medicaid ( CMS) ( will be used to 
translating ICD-9 CM to ICD-10 CM (CMS, 2018).  
The As-Treated  (AT) analysis will be conducted for the safety evaluation. The first 
incidence of a cardiovascular event after the index date and before the 30 days after the end of treatment will be analyzed . 
A cardiovascular event is the first incidence of the composite endpoint of nonfatal MI, 
nonfatal stroke, or in -hospital cardiovascular death ; the first incidence of the composite 
incidence of nonfatal MI, nonfatal stroke, heart failure or in-hospital cardiovascular  
death ; or the first incidence of MI , stroke, heart failure, or in -hospital cardiovascular  
death separately.   
7.8.8. Anabolic  Drug Exposure  
The o verall duration of cohort anabolic drug exposure will be summarized for 
PS-matched patients.  
Overall Duration of Anabolic Drug Exposure (day) = Date of last anabolic drug 
prescription fill + Supply days – index date + 1  
 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 46 of 63 
 
 Confidential  
 Consecutive treatment duration is determined from the index date to the last drug supply 
date without any  gap exceed ing  60 days.   
Because the efficacy and safety evaluation s are limited to an 18 -month period, the overall 
duration of the anabolic drug exposure will be cut off at 540 days, even if the patient used 
the anabolic drug (ABL or TPTD) for > 18 months. 
7.8.9. Concomitant Use of Osteoporosis Treatment 
Between the index date and the end of the Treatment Period ( 18 months + 30-day  follow-
up period), use of any osteoporosis treatment options other than ABL or TPTD will be 
summarized for the PS-matched population s. 
7.8.10. Sensitivity Analyses 
7.8.10.1. Population S election  
To evaluate the stability of the PS matched cohorts, 2 different calipers (0.15, 0.3) will be 
carried out to the PS matching. The sensitivity analyses on effectiveness and safety  
endpoints will be performed on these matching populations.  
Sensitivity analyses on effectiveness and safety  endpoints will be performed on sub 
population with each of additional exclusion criteria:  
• Exclud e patients without a minimum  of 12 months of anabolic drug exposure: 
(1) 12-consecutive months of anabolic drug exposure as assessed by medication 
dispensed; and (2) 12-month cumulative anabolic drug exposure during the 18-month follow-up 
• Exclud e patients  with prescriptions dispensed for ≤ 1 month, 3 months, 6 month s, 
and 9 months 
• Exclud e patients with pr evious use of denosumab or zoledronic acid  
7.8.10.2. Safety Endpoints  
All-cause in-hospital death without any restriction  will replace in -hospital cardiovascular 
death as the sensitivity analysis  on secondary safety endpoints.  
The cardiovascular events (MI, stroke, and heart failure)  in the secondary endpoint is the 
first post-index incidence recorded on a hospital claim or physician claim. To evaluate 
possible overestimat ion, new incident of MI, stroke, or heart failure as no previous 
diagnosis in the 183 days prece ding the index date as in the S entinel Initiative ( Cutrona  et 
al, 2013) will be carried as a sensitivity analysis . 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 47 of 63 
 
 Confidential  
 7.8.11. Subgroup Analyses  
The absence of BMD data is a limitation of the study because BMD is often used for risk 
assessment. Instead, we propose to evaluate patients based on previous fracture history, 
which is the greatest predictor of future fracture risk (Banefelt  et al, 2019; 
Balasubramanian  et al, 2019). 
We propose to have a subgroup analysis of patients with previous bisphosphonate use. 
Most (64.7%) of patients in the EU had previously used bisphosphonates (Langdahl  et al, 
2018). Additional subgroup analyses include evaluation of outcomes by age group and by 
race/ethnicity . 
7.8.11.1. Subgroup Analyses for Effectiveness:  
The following subgroup analyses will be performed: 
• Age group: < 75 years vs. ≥ 75 years  
• Race/ethnicity: White, Hispanic, African American, Asian, Other, Unknown, 
Missing  
• Prior use of bisphosphonates within 5 years before the index date: with vs. without 
• Prior fracture within 1 year before the index date: with vs. without 
Each subgroup will be PS-matched separately to ensure the comparability between the 
patients in the ABL and TPTD groups. 
7.8.11.2. Subgroup Analyses for Safety: 
Subgroup analyses will be performed by: 
• Age group (age < 75 years vs. age ≥ 75 years) 
• Race/ethnicity: White, Hispanic, African American, Asian, Other, Unknown, 
Missing   
• With or without prior cardiovascular risk 
• With or without MI or stroke within 1 year before the index date.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 48 of 63 
 
 Confidential  
 Each subgroup will be PS-matched separately to ensure the comparability between ABL 
and TPTD.  
7.9. Quality Assurance  
Outlined by phase below is  PRA Medical Informatics’ Codes Review and Quality 
Control procedure: 
1. Pre-Programming 
Quality Control  In this phase, the Internal Developer will ensure access to all 
data tables is available, as well as ensure all clinical codes 
given by the Clinical Lead are aligned with PRA internal standard reference data management tables in the database.  
2. Code Quality Control Documentation  In this phase, the Internal Developer will ensure the QC documentation captures each step of the coding process and details all requirements each step is required to implement, the database tables used and/or created as well as the desired outcomes.  
3. Code Quality 
Control Review  In this phase, the Internal Developer and the Peer QC Analyst 
will walk through the entirety of the code section by section ensuring the code matches the Technical Specifications Document and is producing the desired outcomes. A Quality Gate Acceptance/Failure designation will be assigned at each step in the QC documentation. If a Quality Gate fails at a specific point, the root cause of the failure will be determined (ie, coding errors, problematic business rules, etc.) and appropriate corrective action will be taken.  
If there has been a coding error, the Internal Developer will correct the error, re -run the code, and produce the requisite 
outputs. If one or more business rules are causing problems, the business rules may need to be modified. Any business rule modifications will need Project Manager sign -off and be 
detailed on any documentation going back to the client.  
Regardless of the fa ilure, the Quality Control phases will be repeated to ensure the issues 
have be corrected. (if so, modifications to the business rules may be necessary to match 
the produced results), or data (if so, additional steps may be required to clean the data as 
needed to achieve the expected results).  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 49 of 63 
 
 Confidential  
 8. PROTECTION OF HUMAN SUBJECTS  
The terms of the Research Exception provisions of the Privacy Rule, 45 CFR 164.514(e) 
exempt Institutional Review Board approval for this non-experimental study, which is fully HIPAA compl iant. Data are maintained in a de-identified manner, thus are not 
subject to institutional review board.  
No patients will be directly contacted for participation in the study and no intervention will be provided as part of the protocol. The study will use a secondary data source containing de-identified data.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 50 of 63 
 
 Confidential  
 9. MANAGEMENT AND REPORTING OF ADVERSE 
EVENTS/ADVERSE REACTIONS  
The design of this study is characterized by secondary use of data previously collected 
from health insurance claims. Thus, for this study the submission of suspected adverse 
reactions in the form of Individual Case Safety Reports (ICSRs) is not required. The 
study design was retrospective and there were no claims adjudication. No validated algorithm was used to confirm events were incident events. Claims are therefore only 
“proxies” for events.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 51 of 63 
 
 Confidential  
 10. PLANS FOR D ISSEMINATING AND  COMMUNICATING 
STUDY  RESULTS  
The study will be registered on ClinicalTrials.gov. The results from this retrospective 
cohort study evaluating real -world evidence will be submitted as a manuscript to a peer -
reviewed journal.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 52 of 63 
 
 Confidential  
 11. REFERENCES  
Austin PC. Optimal caliper widths for propensity -score matching when estimating 
differences in means and differences in proportions in observational studies. Pharm Stat. 
2011;10(2):150-161. doi: 10.1002/pst.433. 
Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle SG, Grauer A, et al. Risk of 
subsequent fracture after prior fracture among older women. Osteoporos Int. 2019; 30: 79-
92. doi: 10.1007/s00198-018-4732-1. 
Banefelt J, Akesson K, Spange us A, Ljunggren O, Karlsson L, Strom O, et al. Risk of 
imminent fracture following a previous fracture in a Swedish  database study. Osteoporos 
Int. 2019;30:601-609. doi: 10.1007/s00198-019-04852-8. 
Barrett-Connor E, Ensrud K, Tosteson AN, Varon SF, Anthony M, Daizadeh N, et al. 
Design of the POSSIBLE UStrade mark Study: postmenopausal women's compliance and 
persistence with osteoporosis medications. Osteoporos Int. 2009;20(3):463-472. 
doi: 10.1007/s00198-008-0674-3. 
Black  DM, Arden NK, Palermo L, Pearson J, Cummings SR. Prevalent vertebral 
deformities predict hip fractures and new vertebral deformities but not wrist fractures. 
Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1999;14(5):821-
828. doi: 10.1359/jbmr.1999.14.5.821. 
Burge R, Dawson, Hughes B, Solomon DH, Wong JB, King A, et al. Incidence and 
economic burden of osteoporosis-related fractures in the United States, 2005 -2025. J 
Bone Miner Res. 2007;22(3):465-475. doi: 10.1080/21556660.2019.1677674. 
Burge RT, Disch DP, Gelwicks S, Zhang X, Krege JH. Hip and other fragility fracture 
incidence in real-world teriparatide- treated patients in the United States. Osteoporos Int.  
2017;28(3):799-809. doi: 10.1007/s00198-016-3888-9. 
Burshell AL, Möricke R, Corr ea-Rotter R, Chen P, Warner MR, Dalsky GP, et al. 
Correlations between biochemical markers of bone turnover and bone density responses 
in patients with glucocorticoid -induced osteoporosis treated with teriparatide or 
alendronate. Bone. 2010;46(4):935-939. doi:  10.1016/j.bone.2009.12.032. 
Sponsor Name:  Radius Health, Inc.  
Protocol Number:  BA058 -05-028 
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 53 of 63 
Conf idential Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American 
Association of Clinical Endocrinologists/American College of Endocrinology Clinical 
Practice Guidelines for the Diagnosis and Treatment of Pos tmenopausal Osteoporosis-
2020 Update. Endocr Pract. 2020;26(Suppl 1):1-46. doi: 10.4158/GL-2020-0524SUPPL. 
Centers for Disease Control and Prevention (CDC). About Underlying Casue of Death, 
1999-2019 at: https://wonder.cdc.gov/ucd-icd10.html. Accessed on June 8, 2021 
Centers 
for Medicare & Medicaid Services (CMS). 2018 ICD-1 0 and GEMS. Available 
at:
 https://www.cms.gov/Medicare/Coding/ICD10/2018-ICD-10-CM-and-G EMs. 
A
ccessed on: June 8, 2021. 
Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, et al. Bone-
forming and antiresorptive effects of romosozumab in postmenopausal women with 
osteoporosis: bone hi stomorphometry and microcomputed tomography analysis after 2 
and 12 months of treatment. J Bone Miner Res. 2019;34(9):1597-1608. 
doi: 10.1002/jbmr.3735. 
Chen CW, Huang TL, Su LT, Kuo YC, Wu SC, Li CY, et al. Incidence of subsequent hip 
fractures i s signific antly i ncreased within t he first month af ter distal r adius  fracture in 
patients older than 60 years. J Trauma Acute Care Surg. 2013;74(1):317-321. 
doi: 10.1097/ta.0b013e31824bb325. 
Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. C linician’s 
guide to preventi on and treatment of osteoporosis. Osteoporos Int. 2014; 25:2359-2381. 
doi: 10.1007/s00198-014-2794-2. 
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. 
Romosozumab t reatment  in pos t menopausal w omen w ith osteoporosis. N Engl J Med. 
2016;375(16):1532-1543. doi: 10.1056/NEJMoa1607948. 
Cosman F , Nieves J W, D empster D W. T reatment  Sequence Matters: A naboli c and  
Antiresorptive Therapy for Osteoporosis. J Bone Miner Res. 2017;32(2):198-202. 
doi: 10.1002/jbmr.3051. 
Cosman F, Peterson LR, Towler DA, Mitlak B, Wang Y, Cummings SRl. Cardiovascular 
safety of a baloparatide in postmenopausal w om en w ith osteoporosis: analysis from the 
ACTIVE Phase 3 t rial. J Clin Endocrinol Metab. 2020;105(11):3384-3395. 
doi: 10.1210/clinem/dgaa450. 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 54 of 63 
 
 Confidential  
 Cummings SR, Melton LJ III. Epidemiology and outcomes of osteoporotic fractures. 
Lancet. 2002;359(9319):1761-1767. doi: 10.1016/S0140-6736(02)08657-9. 
Cutrona SL, Toh S, Iyer A, Foy S, Daniel GW, Nair VP, et al. Validation of acute 
myocardial infarction in the Food and Drug Administration's Mini‐Sentinel program. Pharmacoepidemiol Drug Saf. 2013;22(1):40-54. doi.org/10.1002/pds.3310. 
Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359(9322):2018-
26. doi: 10.1016/S0140-6736(02)08827-X.  
Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, et al. Differential effects of teriparatide and denosumab on intact PTH and bone formation 
indices: AVA Osteoporosis Study. J Clin Endocrinol Metab. 2016;101(4):1353-63. 
doi: 10.1210/jc.2015-4181. 
Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, et al. Remodeling- and modeling -based bone formation with teriparatide versus denosumab: a 
longitudinal analysis from baseline to 3 months in the AVA Study. J Bone Miner Res. 2018;33(2):298-306. doi: 10.1002/jbmr.3309. 
Ensrud KE, Blackwell TL, Cawthon PM, Bauer DC, Fink HA, Schousboe JT, et al; 
Osteoporotic Fractures in Men (MrOS) Study of Osteoporotic Fractures (SOF) Research 
Groups. Degree of Trauma Differs for Major Osteoporotic Fracture Events in Older Men 
Versus Older Women. J Bone Miner Res. 2016;31(1):204-207. doi: 10.1002/jbmr.2589. 
European Medicines Agency (EMA). Committee for Medicinal Products for Human Use 
(CHMP). Guideline on the choice of the non -inferiority margin. London, United 
Kingdom; July 2005. Doc. Ref. EMEA/CPMP/EWP/2158/99. 
Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, et al. Emulating randomized clinical trials with nonrandomized real -world evidence  studies: first results 
from the RCT DUPLICATE Initiative. Circulation. 2021 Mar 9;143(10):1002-1013. doi: 
10.1161/CIRCULATIONAHA.120.051718. 
Fuggle NR, Cooper C, Harvey NC, Al-Daghri N, Brandi ML, Bruyere O, et al. 
Assessment of cardiovascular safety of a nti-osteoporosis drugs. Drugs. 
2020;80(15):1537-1552. doi: 10.1007/s40265-020-01364-2. 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 55 of 63 
 
 Confidential  
 Gold DT, Williams SA, Weiss RJ, Wang Y, Watkins C, Carroll J, et al. Impact of 
fractures on quality of life in patients with osteoporosis: a US cross -sectional survey. J  
Drug Assess. 2019;8(1):175-183. doi: 10.1080/21556660.2019.1677674. 
Hochberg M. Preventing fractures in postmenopausal women with osteoporosis. A 
review of recent controlled trials of antiresorptive agents. Drugs Aging. 2000;17(4):317-
30. doi: 10.2165/00002512-200017040-00007. 
Imel EA, Starzyk K, Gliklich R, Weiss RJ, Wang Y, Williams SA. Characterizing 
patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis. Osteoporos Int. 2020;31(12):2413-2424. 
doi: 10.1007/s00198-020-05388-y. 
International Osteoporosis Foundation (IOF). Facts and Statistics. Nyon, Switzerland, 
IOF; 2020. Available from: https://www.iofbonehealth.org/facts-statistics#category -14. 
Accessed on May 15, 2020. 
Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA. Symptomatic 
fracture incidence in elderly men and women: the Dubbo Osteoporos is Epidemiology 
Study (DOES). Osteoporosis Int. 1994;4(5):277-282. doi: 10.1007/BF01623352. 
Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, et al. A meta- analysis 
of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375-82. 
doi: 10.1016/j.bone.2004.03.024. 
Kochanek KD, Murphy SL, Xu JQ, Tejada-Vera B. Deaths: final data for 2014. National 
vital statistics reports; vol 65, no 4. Hyattsville, MD: National Center for Health 
Statistics. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr65/nvsr65_04.pdf. 
Accessed: November 4, 2019. 
Langdahl BL, Silverman S, Fujiwara S, Saag K, Napoli N, Soen S, et al. Real -world 
effectiveness of teriparatide on fracture reduction in patients with osteoporosis and 
comorbidities or risk factors for fractures: Integrated analysis of 4 pros pective 
observational studies. Bone. 2018;116:58-66. doi: 10.1016/j.bone.2018.07.013. 
Li G, Ioannidis G, Pickard L, Kennedy C, Papaioannou A, Thabane L, et al. Frailty index 
of deficit accumulation and falls: data from the Global Longitudinal Study of 
Osteoporosis in Women (GLOW) Hamilton cohort. BMC Musculoskelet Disord. 
2014;15:185. doi: 10.1186/1471-2474-15-185. 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 56 of 63 
 
 Confidential  
 Li G, Papaioannou A, Thabane L, Cheng J, Adachi JD. Frailty Change and Major 
Osteoporotic Fracture in the Elderly: Data from the Global Longitud inal Study of 
Osteoporosis in Women 3-Year Hamilton Cohort. J Bone Miner Res. 2016;31(4):718-24. 
doi: 10.1002/jbmr.2739. 
Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new 
vertebral fracture in the year following a fracture. JAMA. 2001;285(3):320-3. 
doi: 10.1001/jama.285.3.320. 
Litwic A, Lekarz, Warwick D, Denniston E. Distal radius fracture: Cinderella of the osteoporotic fractures. Orthop Muscul Syst. 2014;3(3):162-168. doi: 10.4172/2161-
0533.1000162. 
McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following 
discontinuation of long-term denosumab therapy. Osteoporosis International. 2017;28(5):1723-1732. doi: 10.007/s00198-3919-1. 
Nazrun AS, Tzar MN, Mokhtar SA, Mohamed IN. A systematic review of the out comes 
of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, 
and mortality. Ther Clin Risk Manag. 2014;10:937-948. doi: 10.2147/TCRM.S72456. 
Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, et al.  
Sustained nonvertebral fragility fracture risk reduction after discontinuation of 
teriparatide treatment. J Bone Miner Res. 2005;20(9):1507-1513. doi: 10.1359/JBMR.050501. 
Ritchey MD, Loustalot F, Wall HK, Steiner CA, Gillespie C, George MG,  et al. Millio n 
Hearts: description of the national surveillance and modeling methodology used to 
monitor the number of cardiovascular events prevented during 2012–2016. Journal of the American Heart Association. 2017;6(5):e006021. doi: 10.1161/JAHA.117.006021. 
Rizzoli R, Bonjour JP, Ferrari SL. Osteoporosis, genetics and hormones. J Mol 
Endocrinol. 2001;26(2):79-94. doi: 10.1677/jme.0.0260079. 
Robinson CM, Royds M, Abraham A, McQueen MM, Court-Brown CM, Christie J. 
Refractures in patients at least forty -five years old. a prospective analysis of twenty -two 
thousand and sixty patients. J Bone Joint Surg Am. 2002;84(9):1528-33. 
doi: 10.2106/00004623-200209000-00004. 
Sponsor Name:  Radius Health, Inc.  
Protocol Number:  BA058 -05-028 
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 57 of 63 
Conf idential Rosier RN. Expanding the role of the orthopaedic surgeon in the treatment of 
osteoporosis. Clin Orthop Relat Res. 2001;(385):57-67. doi: 10.1097/00003086-
200104000-00011. 
Ross PD. Osteoporosis. Frequency, consequences, and risk factors. Arch Intern Med. 
1996;156(13):1399-411. doi: 10.1001/archinte.156.13.1399. 
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. 
Romosozumab or Alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. 
Samelson EJ, Kiel DP, Broe KE, Zhang Y, Cupples LA, Hannan MT, et al . Metacarpal 
cortical area and risk of coronary heart disease: the Framingham Study. Am J Epidemiol. 
2004;159(6):589-595. doi: 10.1093/aje/kwh080. 
Suzuki N, Ogikubo O, Hansson T. The course of the acute vertebral body fragility 
fracture: its effect on pain, disability and quality of life during 12 months. Eur Spine J. 
2008;17(10):1380-1390. doi: 10.1007/s00586-008-0753-3. 
Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. 
Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005;20(11):1912-1920. doi: 10.1359/JBMR.050711. Erratum in: J 
Bone Miner Res. 2006 Feb;21(2):352. 
Tashjian AH Jr, Gagel RF. Teriparatide [human PTH(1 -34)]: 2.5 years of experience on 
the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res. 
2006;21(3):354-365. doi: 10.1359/JBMR.051023. 
Tosi LL, Lane JM. Osteoporosis prevention and the orthopaedic surgeon: when fracture 
care is not enough. J Bone Joint Surg Am. 1998;80(11):1567-1569. doi: 10.2106/00004623-199811000-00001. 
Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd. Impact 
of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int. 
2001;12(12):1042-1049. doi: 10.1007/s001980170015. 
Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, et 
al. Discontinuation of Denosumab therapy for osteoporosis: a systematic review and 
position statement by ECTS. Bone. 2017;105:11-17. doi: 10.1016/j.bone.2017.08.003. 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 58 of 63 
 
 Confidential  
 United States Food and Drug Administration (FDA). Guidance for Industry: Non-
Inferiority Clinical Trials to Establish Effectiveness. Silver Spring, MD, USA; 2016.  
United States Food and Drug Administration (FDA). Sentinel Initiative: Health 
Outcomes of Interest. Available at: http://www.sentinelinitiative.org/methods -data-
tools/health -outcomes-interest. Accessed: April 18, 2021.  
Williams SA, Weiss RJ, Wang Y, Cui L, Nichols H, Gernert A. Characterization of patients new to osteoporosis therapies. In Academy of Managed Care Pharmacy Supplement. 2019;25(3a). 
World Health Organization (WHO). Assessment of osteoporosis at the primary health 
care level. Summary of a WHO Scientific Group 2007 [16 Feb 2017]. Available from: 
www.who.int/chp/topics/rhuematic/en/index.html  
Wright NC, Daigle SG, Melton ME, Delzell ES, Balasubramanian A, Curtis JR. The design and validation of a new algorithm to identify incident fractures in administrative 
claims data. J Bone Miner Res. 2019;34(10):1798-1807. doi: 10.1002/jbmr.3807. 
Yusuf AA, Cummings SR, Watts NB, Feudjo MT, Sprafka JM, Zhou J, et al. Real -world 
effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women. 
Arch Osteoporos. 2018;13(1):33. doi: 10.1007/s11657-018-0439-3. 
Xie F, Colantonio LD, Curtis JR, Kilgore ML, Levitan EB, Monda KL, et al . 
Development of algorithms for identifying fatal cardiovascular disease in Medicare 
claims. Pharmacoepidemiology and drug safety. 2018;27(7):740-750. doi: 10.1002/pds.4421. 
Zanchetta MB, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta JR. Significant 
bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporosis Int. 2018;29(1):41-47. doi: 10.1007/s00198-017-4242-6. 
 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 59 of 63 
 
 Confidential  
 12. APPENDICES  
Appendix  1: List of Parameters for Propensity Score Matching 
 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 60 of 63 
 
 Confidential  
 Appendix 2: Fracture Algorithm  
A claims -based algorithm with high specificity for fracture site will be used for 
evaluation of treatment effectiveness  (Wright et al, 2019). 
1. All claims with a fracture diagnosis in any position will be evaluated starting 5 
years before index to 19 months (18 months plus 30 days follow up, 1 month = 30 
days) after index date.  
2. Case -qualifying (CQ) fractures are those identified during an inpatient stay or in 
an outpatient setting accompanied by a fracture repair  procedure code on the same 
day. 
3. CQ fracture diagnoses and non-CQ fracture diagnoses will then be used to extend the fracture episode for evaluation of subsequent fractures. Episodes at the same site continued until a gap of 90 days is observed between consecutive claims.  
Fracture diagnoses will be based on primary or secondary ICD-9 code before October 2015 or ICD-10 code after that date listed on the same claim.  
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 61 of 63 
 
 Confidential  
 Appendix  3: Cardiovascular Event Codes  
 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 62 of 63 
 
 Confidential  
 Appendix  4: Diagnostic Codes for All Comorb idities  
 
Sponsor Name:  Radius Health, Inc.   
Protocol Number:  BA058 -05-028  
Protocol Version and Date:  Original, V1.0 , dated 09 July 2021  Page 63 of 63 
 
 Confidential  
 Appendix  5: National Drug Code (NDC) Codes and HCPCS Codes for 
the Medications Used  